Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
about
Vitamin D compounds for people with chronic kidney disease not requiring dialysisVitamin D compounds for people with chronic kidney disease requiring dialysisKidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Vitamin d receptor activators and clinical outcomes in chronic kidney disease.Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals.Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate dietEffects of treatment of renal osteodystrophy on bone histology.Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.Cellular changes following direct vitamin D injection into the uraemia-induced hyperplastic parathyroid gland.Which vitamin D in CKD-MBD? The time of burning questions.Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activationThe Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.
P2860
Q24240439-18CB1B94-EC42-4504-BA24-97D433D5FDD7Q24240582-93EAD4AA-ED1F-48E4-8F89-FC6912995F30Q33862710-935F09C6-C9C8-4467-9619-98439C4CF73CQ33917786-7D4720EB-732E-4B8B-B8F5-EBFD7A2C7D7DQ34483554-24A5865C-661D-4029-901D-9577DDE34B38Q35020986-06C09951-F037-44CA-B504-E6614FF0632EQ36089390-7C47E1BE-21C4-450A-95E5-4166FD1CA326Q36438261-48C21B0C-2B08-415F-A190-1C9116161160Q37319124-5B5CCBA4-23D6-426B-AE0D-8E232202EF6CQ37690771-7FC02B64-8A62-4E44-8C86-362E0A089613Q38803449-31493B52-E686-4147-A2A2-5E6D46DA23FAQ39369808-B82A3280-4D10-4E2B-A289-D6F619F95A4FQ40318184-B4866FEC-5E70-4C97-8C68-75E6C411830CQ42562972-9B225430-6FAA-4885-98E4-5E9AA50D2E4AQ42727533-C58E359E-D365-43A6-822E-4DA1E5BEFE89Q50101289-39EF1D9F-6AAF-4808-BFAE-8685E5753CB4
P2860
Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Efficacy of 19-Nor-1,25-(OH)2D ...... isease in experimental uremia.
@en
Efficacy of 19-Nor-1,25-(OH)2D ...... isease in experimental uremia.
@nl
type
label
Efficacy of 19-Nor-1,25-(OH)2D ...... isease in experimental uremia.
@en
Efficacy of 19-Nor-1,25-(OH)2D ...... isease in experimental uremia.
@nl
prefLabel
Efficacy of 19-Nor-1,25-(OH)2D ...... isease in experimental uremia.
@en
Efficacy of 19-Nor-1,25-(OH)2D ...... isease in experimental uremia.
@nl
P2093
P1433
P1476
Efficacy of 19-Nor-1,25-(OH)2D ...... isease in experimental uremia.
@en
P2093
Andriana Dusso
Eduardo Slatopolsky
Jane Finch
Jee Webster
Marc Staniforth
P304
P356
10.1046/J.1523-1755.2003.00029.X
P407
P577
2003-06-01T00:00:00Z
P5875
P6179
1010686447